Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
BUSINESS
Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt
Company asked data-monitoring committee to make ruling after another trial was stopped
By AUSTEN HUFFORD
Oct. 10, 2016 8:19 a.m. ET
0 COMMENTS
Alnylam Pharmaceuticals Inc. said a phase 3 trial for one of its drugs would continue, potentially easing investor concerns over the safety of its portfolio.

The company said a data-monitoring committee for its Phase 3 study of the drug patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, an inherited, progressive, life-threatening disease that can cause sensory and motor dysfunction resulting in disability and death, would continue. Patients have a life expectancy of five to 15 years after the onset of symptoms.

The company asked the committee to make its ruling after another one of its closely watched trials was stopped last week after patient deaths.


Last Thursday, the company’s shares plummeted 46% after the company said it would stop a late-stage trial of its drug revusiran, a potential treatment for hereditary ATTR amyloidosis with cardiomyopathy, after 18 patients died.

Shares rose 2.1% in light premarket trading.

“We’re pleased to learn of the DMC’s recommendation that dosing can continue,” Chief Medical Officer Akshay Vaishnaw said.

The company’s central therapeutic approach is a method of turning off certain genes called RNA interference, which has showed promise in recent years.

Results of the trial are expected in mid-2017.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.